Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Classifica tra le azioni #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Prezzo delle azioni
$17.64
Capitalizzazione di mercato
$32.65B
Variazione (1 giorno)
-3.24%
Variazione (1 anno)
-23.70%
Paese
JP
Scambia Daiichi Sankyo Company, Limited (DSNKY)

Categoria

Rapporto P/S per Daiichi Sankyo Company, Limited (DSNKY)
Rapporto P/S al March 2026 TTM: 2.54
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Daiichi Sankyo Company, Limited, il rapporto P/S attuale (TTM) è 2.54. Alla fine del 2024, era pari a 5.59.
Storico del rapporto P/S per Daiichi Sankyo Company, Limited da 2000 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 2.54 -27.98%
2025 3.53 -36.82%
2024 5.59 -22.73%
2023 7.23 47.08%
2022 4.92 -24.35%
2021 6.50 32.44%
2020 4.91 27.54%
2019 3.85 58.68%
2018 2.42 37.56%
2017 1.76 0.78%
2016 1.75 19.75%
2015 1.46 33.47%
2014 1.09 -10.61%
2013 1.22 8.22%
2012 1.13 -3.23%
2011 1.17 -9.73%
2010 1.29 -6.61%
2009 1.39 -42.59%
2008 2.41 -14.72%
2007 2.83 33.04%
2006 2.13 15.39%
2005 1.84 23.64%
2004 1.49 19.99%
2003 1.24 -38.43%
2002 2.02 -16.38%
2001 2.41 95.22%
2000 1.24 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
14.26 460.81%
US
4.96 95.14%
GB
6.18 143.06%
US
6.35 149.82%
US
5.18 103.62%
CH